Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
| Revenue (Most Recent Fiscal Year) | $105.96M |
| Net Income (Most Recent Fiscal Year) | $-81.13M |
| PE Ratio (Current Year Earnings Estimate) | 28.79 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 19.35 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 7.75 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -75.26% |
| Net Margin (Trailing 12 Months) | -76.56% |
| Return on Equity (Trailing 12 Months) | -26.00% |
| Return on Assets (Trailing 12 Months) | -20.57% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.88 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.88 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.59 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.55 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.08 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.08 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 73.75M |
| Free Float | 49.04M |
| Market Capitalization | $2.05B |
| Average Volume (Last 20 Days) | 0.55M |
| Beta (Past 60 Months) | 1.20 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 33.51% |
| Percentage Held By Institutions (Latest 13F Reports) | 92.89% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |